Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems

FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.

FDA concerns about the device Sanofi proposed to deliver two anti-diabetic agents will prolong the review of the combination product, and the delay likely will cause the company to forfeit the advantage gained from the expensive priority review voucher that it used to even the race to market with Novo Nordisk AS.

Sanofi announced Aug. 19 that FDA had requested more information on the pen delivery device that it has proposed for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet